OBJECTIVE: Epithelial ovarian cancer (EOC) cells with CD44 and CK19 coexpression may represent a subset of ovarian cancer stem cells (OCSCs). This study was conducted to evaluate the correlation of the frequency of putative OCSCs (CD44 + CK19 + OCSCs) with the clinicopathologic features and the prognostic value in patients with recurrent advanced stage EOC. METHODS: A retrospective study was carried out on 33 patients with EOC and a uniformly treated tissue microarray was constructed. A multiplexed, immunofluorescence-based method of automated in situ quantitative measurement of protein analysis was used for evaluation of the frequency or density of CD44 + CK19 + OCSCs in EOC. RESULTS: The mean follow-up time was 42.8 ± 27.1 months. High frequency of EOC cells with CD44+ or CD44+/CK19+ was associated with chemoresistance (P = .033 and P = .02, respectively). Using K-M analysis with log-rank test, a high frequency of putative OCSCs was associated with short disease-free interval (7.9 months vs 20.9 months, P = .019). In univariable analysis, the frequency of OCSCs, International Federation of Gynecology and Obstetrics stage and residual tumor volume were significant predictor variables and were entered into multivariable analysis (P = .019, .037, and .005, respectively). Although no independent significant predictor was found, the frequency of putative OCSCs was the most promising predictor variable compared with the other 2 variables (hazard ratio = 2.344, P = .052). CONCLUSION: Our findings suggest that high frequency of OCSCs (CD44+ and CK19+) in epithelial ovarian tumors correlates with short progression-free intervals.
OBJECTIVE:Epithelial ovarian cancer (EOC) cells with CD44 and CK19 coexpression may represent a subset of ovarian cancer stem cells (OCSCs). This study was conducted to evaluate the correlation of the frequency of putative OCSCs (CD44 + CK19 + OCSCs) with the clinicopathologic features and the prognostic value in patients with recurrent advanced stage EOC. METHODS: A retrospective study was carried out on 33 patients with EOC and a uniformly treated tissue microarray was constructed. A multiplexed, immunofluorescence-based method of automated in situ quantitative measurement of protein analysis was used for evaluation of the frequency or density of CD44 + CK19 + OCSCs in EOC. RESULTS: The mean follow-up time was 42.8 ± 27.1 months. High frequency of EOC cells with CD44+ or CD44+/CK19+ was associated with chemoresistance (P = .033 and P = .02, respectively). Using K-M analysis with log-rank test, a high frequency of putative OCSCs was associated with short disease-free interval (7.9 months vs 20.9 months, P = .019). In univariable analysis, the frequency of OCSCs, International Federation of Gynecology and Obstetrics stage and residual tumor volume were significant predictor variables and were entered into multivariable analysis (P = .019, .037, and .005, respectively). Although no independent significant predictor was found, the frequency of putative OCSCs was the most promising predictor variable compared with the other 2 variables (hazard ratio = 2.344, P = .052). CONCLUSION: Our findings suggest that high frequency of OCSCs (CD44+ and CK19+) in epithelial ovarian tumors correlates with short progression-free intervals.
Authors: A Psyrri; P Kountourakis; Z Yu; C Papadimitriou; S Markakis; R L Camp; T Economopoulos; M A Dimopoulos Journal: Ann Oncol Date: 2007-01-13 Impact factor: 32.976
Authors: Patrick C Hermann; Stephan L Huber; Tanja Herrler; Alexandra Aicher; Joachim W Ellwart; Markus Guba; Christiane J Bruns; Christopher Heeschen Journal: Cell Stem Cell Date: 2007-09-13 Impact factor: 24.633
Authors: Niravkumar R Patel; Aleksandr Piroyan; Srinivas Ganta; Allison B Morse; Katie M Candiloro; April L Solon; Abbegail H Nack; Corin A Galati; Collete Bora; Marisa A Maglaty; Shane W O'Brien; Samuel Litwin; Barbara Davis; Denise C Connolly; Timothy P Coleman Journal: Cancer Biol Ther Date: 2018-05-08 Impact factor: 4.742
Authors: Natalia J Sumi; Eydis Lima; John Pizzonia; Sean P Orton; Vinicius Craveiro; Wonduk Joo; Jennie C Holmberg; Marta Gurrea; Yang Yang-Hartwich; Ayesha Alvero; Gil Mor Journal: J Vis Exp Date: 2014-11-02 Impact factor: 1.355
Authors: Vinicius Craveiro; Yang Yang-Hartwich; Jennie C Holmberg; Won Duk Joo; Natalia J Sumi; John Pizzonia; Brian Griffin; Sabrina K Gill; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Ayesha B Alvero; Gil Mor Journal: Cancer Med Date: 2013-08-27 Impact factor: 4.452
Authors: Carmela Ricciardelli; Noor A Lokman; Carmen E Pyragius; Miranda P Ween; Anne M Macpherson; Andrew Ruszkiewicz; Peter Hoffmann; Martin K Oehler Journal: Oncotarget Date: 2017-03-14